8-K: Oramed Pharmaceuticals Invests $36.9 Million in Alpha Tau Medical, Forms Strategic Collaboration

Oramed Pharmaceuticals announces a $36.9 million investment in Alpha Tau Medical, alongside a strategic collaboration to support Alpha Tau's cancer therapy technology.

Summary

• Oramed Pharmaceuticals has invested $36.9 million in Alpha Tau Medical through a registered direct offering, purchasing approximately 14.1 million ordinary shares at $2.612 per share.
• The companies have also entered into a three-year service agreement where Oramed will provide investor relations, strategic guidance, and capital markets expertise to Alpha Tau.
• Oramed will appoint two directors to Alpha Tau's Board of Directors, taking an active governance role.
• The collaboration aims to leverage Oramed's expertise to support Alpha Tau's market presence and accelerate its commercialization efforts.
• Alpha Tau will pay Oramed an aggregate non-refundable fee of $3,000,000 for the services, with $500,000 payable upon execution of the Strategic Services Agreement and the remaining $2,500,000 payable in five equal installments every six months following the date of the Strategic Services Agreement.
• Subject to shareholder approval, Alpha Tau will issue warrants to Oramed to purchase up to 2,390,000 Ordinary Shares at an exercise price $3.90 per share and warrants to purchase up to 847,000 Ordinary Shares at an exercise price of $3.474 per share.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the strategic investment, collaboration, and anticipated benefits for both companies. The management comments are optimistic, and the focus is on future growth and milestones.

Positives

• Oramed gains access to Alpha Tau's innovative alpha-radiation cancer therapy.
• Alpha Tau receives a significant investment to accelerate clinical trials, manufacturing, and commercialization.
• The partnership unites two companies with a shared vision of revolutionizing therapeutic delivery.
• Oramed's strategic capital markets expertise can benefit Alpha Tau's growth.
• Alpha Tau gains access to Oramed's investor relations and public relations management services in certain territories including the United States, Israel and South Korea.

Risks

• Uncertainties exist regarding the satisfaction of closing conditions for the contemplated transactions.
• The success of Alpha Tau's technology is subject to clinical trial outcomes and regulatory approvals.
• The collaboration's success depends on the effective integration of both companies' expertise and resources.
• Alpha Tau's shareholders need to approve the warrant issuance to Oramed.

Future Outlook

The collaboration is expected to accelerate Alpha Tau's clinical and commercial roadmap, with Oramed providing strategic support and capital markets expertise.

Management Comments

• Nadav Kidron (Oramed CEO) believes the alliance represents an exceptional opportunity to support a groundbreaking medical technology.
• Uzi Sofer (Alpha Tau CEO) is delighted to welcome Oramed as a strategic partner and leverage their expertise in capital markets.

Industry Context

This announcement reflects a trend of pharmaceutical companies investing in and collaborating with innovative therapeutic delivery technology companies to enhance their pipelines and market reach.

Comparison to Industry Standards

• Similar strategic investments and collaborations are common in the pharmaceutical industry, where companies seek to leverage external expertise and technologies.
• Comparable companies include those involved in targeted radiation therapies and oral drug delivery systems, such as Actinium Pharmaceuticals and Entera Bio.
• The size of the investment is within the typical range for strategic partnerships in the biotech sector.

Stakeholder Impact

• Shareholders of both Oramed and Alpha Tau may benefit from the strategic collaboration and potential growth.
• Alpha Tau's employees may see increased opportunities due to the investment and expansion.
• Patients may benefit from the accelerated development and commercialization of Alpha Tau's cancer therapy.
• Oramed's employees may see increased opportunities due to the expansion into Alpha Tau's business.

Next Steps

• Oramed will appoint two directors to Alpha Tau's Board of Directors within three months.
• Alpha Tau will seek shareholder approval for the warrant issuance to Oramed.
• Alpha Tau will continue its clinical trials and commercialization efforts with Oramed's support.
• Alpha Tau will register the Ordinary Shares issuable upon exercise of the IR/PR Warrants for resale by Oramed within 60 days of the effective date of the Strategic Services Agreement and to have such resale registration statement declared effective within 90 days of the date of the Strategic Services Agreement (or in the event of a full review by the SEC, 120 days following the date of the Strategic Services Agreement.

Key Dates

Keywords

Alpha Tau Medical, Oramed Pharmaceuticals, Strategic Investment, Cancer Therapy, Alpha DaRT, Investor Relations, Board of Directors, Therapeutic Delivery